Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis
Calciphylaxis in end-stage renal disease is characterized by painful necrotic skin ulcers and high mortality. There are no approved therapies. SNF472, an intravenous formulation of myo-inositol hexaphosphate, inhibits the formation and growth of hydroxyapatite crystals, the final common pathway in the pathogenesis of vascular calcification.
In this open-label, single-arm study, calciphylaxis patients on thrice-weekly hemodialysis and standard care, received intravenous SNF472 3 times per week for 12 weeks. The primary endpoint was wound healing assessed using the quantitative Bates-Jensen Wound Assessment Tool (BWAT). Pain visual analog scale (VAS), quality of life (wound-QoL), and qualitative wound image review were secondary endpoints. Quantitative changes from baseline were analyzed by paired t-tests using multiple imputation to account for missing observations.
Fourteen patients received SNF472. Improvements from baseline to week 12 were observed for mean BWAT score (− 8.1; P < 0.001), pain VAS (− 23.6 mm; P = 0.015) and wound-QoL global score (− 0.90; P = 0.003). Of the 9 patients with ulcerated lesions at baseline who completed treatment, wound image review showed improvement for 7. SNF472 was well tolerated with no serious treatment-related adverse events. The most common adverse events were infections which occur frequently in patients on hemodialysis. None of these were considered as treatment-related.
SNF472 was well-tolerated and improvements from baseline to week 12 in wound healing, pain, and quality of life were observed. A randomized, double-blind, placebo-controlled trial is planned to evaluate SNF472 in patients with calciphylaxis.
KeywordsSNF472 Calciphylaxis Dialysis myo-inositol hexaphosphate CUA
The study was supported by Laboratoris Sanifit. Medical writing support from Jonathan Latham of PharmaScribe, LLC was funded by Sanifit. The study was conducted in the US at Frenova Renal Research® and Davita Kidney Care sites, and in the UK at the Salford Royal NHS Foundation Trust. Sanifit thanks Dr. Barbara Bates-Jensen for permission to use the BWAT in this study.
VB, SS, JT, AZC, PJ, CS, and JP contributed to the study concept and design. VB and SS contributed to the acquisition of data. VB, SS, RG, SM, AZC, CS, KJC, AG, and JP contributed to the conduct, analysis and interpretation of the data. SM and RG drafted the article. All authors contributed to critical editing and revising the article for important intellectual content. All authors provided final approval of the version to be published. All authors agree to be accountable for all aspects of the work.
Compliance with ethical standards
Conflict of interest
VB is a consultant to Pharmacosmos, Vifor, and FMC, received lecture fees from Amgen, Pfizer, Bayer, Pharmacosmos, Vifor, FMC, Servier, Novartis, Daiichi-Sankyo, and Cardiobridge, received a grant for the European Calciphylaxis Network EuCalNet from Amgen, and received grants from Pfizer, Bayer, Sanifit, Pharmacosmos, Vifor, FMC, Servier, Novartis, Daiichi-Sankyo, and Cardiobridge. SS is a consultant to Sanifit, and received lecture fees from Vifor Fresenius, MSD, and Boehringer Ingelheim. JT has no conflicts to disclose. KJC and PJ, are consultants to Sanifit. RG, SM and AG are employees and shareholders of Sanifit Therapeutics. AZC is an employee and shareholders of Sanifit and has a patent pending related to SNF472. CS is an employee of Sanifit and has patents related to SNF472. JP is an employee and shareholder of Sanifit, and has patents owned or controlled by Sanifit.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Patients gave written informed consent to participate.
- 2.Nunley JR (2017) Calciphylaxis. https://emedicine.medscape.com/article/1095481-overview. Accessed 1 June 2019
- 6.Budisavljevic MN, Cheek D, Ploth DW (1996) Calciphylaxis in chronic renal failure. J Am Soc Nephrol 7:978–982Google Scholar
- 9.Sanguankeo A, Thamcharoen N, Upala S (2017) Calciphylaxis in a nondialysis patient treated with sodium thiosulfate and high dose of oxygen. Clin Nephrol Case Stud 5:38–41Google Scholar
- 12.Hafner J, Keusch G, Wahl C, Sauter B, Hurlimann A, von Weizsacker F, Krayenbuhl M, Biedermann K, Brunner U, Helfenstein U (1995) Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. J Am Acad Dermatol 33:954–962CrossRefGoogle Scholar
- 15.Auriemma M, Carbone A, Di Liberato L, Cupaiolo A, Caponio C, De Simone C, Tulli A, Bonomini M, Amerio P (2011) Treatment of cutaneous calciphylaxis with sodium thiosulfate: two case reports and a review of the literature. Am J Clin Dermatol 12:339–346. https://doi.org/10.2165/11587060-000000000-00000 CrossRefGoogle Scholar
- 18.Ferrer MD, Ketteler M, Tur F, Tur E, Isern B, Salcedo C, Joubert PH, Behets GJ, Neven E, D’Haese PC, Perello J (2018) Characterization of SNF472 pharmacokinetics and efficacy in uremic and non-uremic rats models of cardiovascular calcification. PLoS ONE 13:e0197061. https://doi.org/10.1371/journal.pone.0197061 CrossRefGoogle Scholar
- 20.Perelló J, Gómez M, Ferrer MD, Rodríguez NY, Salcedo C, Buades JM, Pérez MM, Torregrosa JV, Martín E, Maduell F (2018) SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels. J Nephrol 31:287–296. https://doi.org/10.1007/s40620-018-0471-9 CrossRefGoogle Scholar
- 21.Perelló J, Joubert PH, Ferrer MD, Canals AZ, Sinha S, Salcedo C (2018) First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification. Br J Clin Pharmacol 84:2867–2876. https://doi.org/10.1111/bcp.13752 CrossRefGoogle Scholar
- 22.Bates-Jensen BM, Vredevoe DL, Brecht ML (1992) Validity and reliability of the pressure sore status tool. Decubitus 5:20–28Google Scholar
- 24.Olsen MF, Bjerre E, Hansen MD, Tendal B, Hilden J, Hróbjartsson A (2018) Minimum clinically important differences in chronic pain vary considerably by baseline pain and methodological factors: systematic review of empirical studies. J Clin Epidemiol 101:87–106.e2. https://doi.org/10.1016/j.jclinepi.2018.05.007 CrossRefGoogle Scholar
- 25.Olsen MF, Bjerre E, Hansen MD, Hilden J, Landler NE, Tendal B, Hróbjartsson A (2017) Pain relief that matters to patients: systematic review of empirical studies assessing the minimum clinically important difference in acute pain. BMC Med 15:35. https://doi.org/10.1186/s12916-016-0775-3 CrossRefGoogle Scholar
- 26.Torregrosa JV, Ramos AM (2010) Use of bisphosphonates in chronic kidney disease. Nefrologia 30:288–296Google Scholar
- 27.Torregrosa JV, Duran CE, Barros X, Blasco M, Arias M, Cases A, Campistol JM (2012) Successful treatment of calcific uraemic arteriolopathy with bisphosphonates. Nefrologia 32:329–334Google Scholar
- 29.Riemer CA, El-Azhary RA, Wu KL, Strand JJ, Lehman JS (2017) Underreported use of palliative care and patient-reported outcome measures to address reduced quality of life in patients with calciphylaxis: a systematic review. Br J Dermatol 177:1510–1518. https://doi.org/10.1111/bjd.15702 CrossRefGoogle Scholar